IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

UNDERSTANDING REGULATION FOR THE STUDY OF PRESCRIPTION DRUG LABELLING REQUIREMENTS IN USFDA, EMA AND CDSCO

Divya P. Vinchurkar*, Chetan T. Choudhari

Maharashtra Institute of Pharmacy (B.Pharm) Betala, Bramhapuri, Chandrapur, Maharashtra-441206

ABSTRACT:

This research provides comparative examination of requirements for prescription labelling in three regulatory super jurisdictions: the United States of America, the European Union, and India. Labelling on drugs is a vital communication means that facilitates proper use of medicine safely and effectively by communicating core information to prescribing physicians and patients. The research comprehensively analyses the regulatory directives for labelling exercises in these regulatory super jurisdictions, which include the guidelines of the U.S. FDA, the European Medicines Agency (EMA), and India's Central Drugs Standard Control Organization (CDSCO). Regulatory expectations regarding key components such as labelling formats, required content, language, and patient safety and risk communication strategies are found to be majorly similar and divergent, depending on differing public health priorities, legal requirements, and cultural norms.

This study identifies regulatory gaps, industry challenges, and potential harmonization strategies to facilitate global trade and enhance consumer confidence. By understanding these frameworks, stake holders can navigate compliance more efficiently, fostering growth in labelling practices across the USA, Europe, and India. The conclusions highlight the necessity of balancing some labelling components to ensure global drug safety while acknowledging the necessity of local adjustments.

KAYWORDS: USFDA, EMA, CDSCO, Drug Labelling, Regulatory Frameworks.

INTRODUCTION:

Definition of Label: A label means any display of written, printed, or graphic matter on the immediate container of any article, or any such matter affixed to any consumer commodity or affixed to or appearing upon a package containing any consumer commodity. a drug label refers to all the printed information included with any dietary supplement, over-the-counter medicine, or prescription drug.

Pharmaceutical labelling, also known as drug labeling or prescription labelling, refers to the written, printed, or graphic information displayed on drugs or their containers, as well as the accompanying

materials. The primary purpose of drug labelling is to identify the contents of the drug and provide specific instructions and warnings regarding its administration, storage, and disposal. Drug labeling serves to identify drug contents, offer guidance, and enable patients to use medication effectively. It also aids healthcare practitioners in prescribing and dispensing medications. Different countries and regions have specific requirements for drug labelling influenced by healthcare systems, past incidents, and commercial considerations.

Importance of Drug Labelling:

Drug labeling serves to identify drug contents, offers guidance, and enables patients to use medication effectively. The primary purpose of labelling medicines is the clear unambiguous identification of the medicine and the conditions for its safe use. It also aids healthcare practitioners in prescribing and dispensing medications. Different countries and regions have specific requirements for drug labelling influenced by healthcare systems, past incidents, and commercial considerations. Drug labeling serves crucial roles in identifying the active ingredients and excipients of a drug and providing guidance to ensure patient safety and appropriate medication administration.



Fig.1 Importance of Drug Labelling

Types of Labelling:

1) Manufacturer label
2) Dispensing label

1) Manufacturer Label-A label which contains drug information for use by medical practitioners,pharmacists,or nurses and is supplied by the manufacturer, packer, or distributor of the drug is a manufacturer label. Rule 96 of the Drug and Cosmetic Rules (manner of Labeling) mandates the minimum information which needs to be put on the label of all medicines.



2) **Dispensing Lalel-** Labels for dispensed medicines are important for communicating medicine-related information to consumers and ensuring effective medicine use. The dispensed medicine label must include the essential information the consumer needs to take their medicines safely and effectively. All dispensed medicines are legally required to have a label before being provided to the consumer.

Mandated requirements vary between states and territories, but include the consumer's name; medicine name, strength and dose form; date of dispensing; and the name and address of the dispensing pharmacy.



Overview of Drug Regulatory Agencies:

Drug regulatory bodies oversee the scientific assessment, approval, and ongoing surveillance of medications to guarantee their safety, effectiveness, and quality. Although their fundamental goals are generally consistent across different regions, the regulatory systems, approval processes, and operational frameworks differ based on legal requirements, public health concerns, and local healthcare demands. This section offers a summary of the three principal regulatory agencies, USFDA, EMA, and CDSCO, that greatly impact global drug development and regulatory approaches.

1) **United States Food and Drug Administration (USFDA):** The federal agency responsible for regulating drugs, biologics, medical devices, and other health-related products in the United States is the United States Food and Drug Administration (USFDA). Functioning under the jurisdiction of the Federal Food, Drug, and Cosmetic (FD&C) Act, the USFDA guarantees that authorized pharmaceutical products comply with set criteria for safety, effectiveness, and quality prior to their entry into the U.S. market. Within the USFDA, the Center for Drug Evaluation and Research (CDER) manages the authorization of small-molecule medications, whereas the Center for Biologics Evaluation and Research (CBER) governs biological products, such as vaccines

and gene therapies.

2) **European Medicines Agency (EMA):** The European Medicines Agency (EMA) serves as the central regulatory body tasked with the scientific assessment and oversight of pharmaceutical products in the European Union (EU). Created to align regulatory decisions among EU member states, the EMA is vital in promoting consistent access to safe and effective medications throughout Europe. The main scientific organization within the EMA is the Committee for Medicinal Products for Human Use (CHMP), which performs benefit–risk evaluations of marketing authorization requests. The Centralized Procedure is compulsory for specific product categories, such as biotechnology-derived medications, orphan drugs, and advanced therapy medicinal products (ATMPs), leading to a single marketing authorization applicable throughout all EU member states.
3) **Central Drugs Standard Control Organization (CDSCO):** The Central Drugs Standard Control Organization (CDSCO) serves as India's national regulatory body overseeing the approval and regulation of pharmaceuticals, medical devices, and clinical research. CDSCO operates under the Ministry of Health and Family Welfare, holding regulatory power based on the Drugs and Cosmetics Act of 1940 and its later amendments. In recent years, CDSCO has experienced considerable regulatory change with the introduction of the New Drugs and Clinical Trials (NDCT) Rules, 2019, designed to simplify approval procedures, improve transparency, and harmonize Indian regulations with global standards.
The agency is responsible for approving new drugs, fixed-dose combinations, biologics, and vaccines, as well as granting permission for clinical trials conducted in India.

Organizational Structure of Regulatory Agencies

Feature	USFDA	EMA	CDSCO
Legal Authority	• FD&C Act	• EU Regulations (Centralized, DCP, MRP)	• Drugs & Cosmetics Act
Responsible Center	• CDER, CBER	• CHMP & Scientific Committees	• DCGI & Subject Expert Committees
Scope	• Drugs, Biologics, Devices	• Drugs, Biologics, Advanced Therapies	• Drugs, Biologics, Vaccines, FDC
Regional Jurisdiction	• USA	• European Union	• India
Transparency	• Advisory Committee meetings, review review summaries	• EPARs, public assessment reports	• Increasing transparency; Clinical trial approvals online

Drug Labelling Requirements in India:

In India, the Central Drugs Standard Control Organization (CDSCO) regulates drug labelling. In India, the CDSCO is regulated by the Ministry of Health and Family Welfare, which oversees pharmaceuticals and cosmetics. The Drugs and Cosmetics Act of 1940 and its subsequent amendments create the legal framework for drug labeling in India. The CDSCO publishes guidelines for labeling formats and content. The Drugs and Cosmetics (Labels) Rules, 1970 are part of the guidelines released by the CDSCO outlining labeling requirements for various categories of drugs.

In India, the Central Drugs Standard Control Organization (CDSCO) regulates drug labelling. In India, the CDSCO is regulated by the Ministry of Health and Family Welfare, which oversees pharmaceuticals and cosmetics. The Drugs and Cosmetics Act of 1940 and its subsequent amendments create the legal

framework for drug labeling in India. The CDSCO publishes guidelines for labeling formats and content. The Drugs and Cosmetics (Labels) Rules, 1970 are part of the guidelines released by the CDSCO outlining labeling requirements for various categories of drugs.

Drug labeling requirements in the USA:

In the United States, the primary regulatory body responsible for medicine labeling is the Food and Drug Administration (FDA). The Federal Food, Drug, and Cosmetic Act (FD&C Act) grants the FDA the authority to establish labeling regulations for prescription and over-the-counter (OTC) drugs. The FDA enforces these regulations via its Center for Drug Evaluation and Research (CDER). Several guidance documents providing detailed instructions on labeling format and content are issued by the CDER. Similar to CDSCO, the US Food and Drug Administration (US FDA) is tasked with regulating and monitoring the safety of food, drugs, vaccines, dietary supplements, biological medical products, blood products, medical devices, and cosmetics. It includes four directorates that oversee the agency's functions alongside the Commissioner's Office.

The Food and Drug Administration (FDA) is updating its regulations regarding the format and substance of labels for human prescription medications, including biological products classified as drugs. The FDA issued a proposed rule to revise the regulations pertaining to the structure and content of labeling for human prescription drug products, as stated in 21 CFR 201.56 and 201.57. The final regulation states that all FDA-approved patient labeling for new, recently approved, and older products must be either reprinted or included with the labeling. Moreover, the final regulation elucidates certain standards in the current guidelines for prescription drug labeling of older products. These adjustments will enable medical experts to gain additional insights from the labeling of previous products.

Guidelines for the format and content of labels for biological products and prescription medications for humans.

Labelling for prescription drugs as outlined in § 201.100(d) must adhere to the following general standards:

• The label must include an overview of the key scientific data required for the medication's safe and efficient usage.

• The labelling must be factual and educational, without any false or misleading information or a commercial tone. The labelling must be revised whenever new information becomes available that makes the labelling incorrect, misleading, or inaccurate in line with this chapter's §§ 314.70 and 601.12.

• Labelling must, if feasible, be grounded in information gleaned from human experience. If there is not enough proof of safety or significant proof of efficacy, no inferred claims or recommendations of drug use may be made.

Labeling requirements for new and more recently approved prescription drug products:

Labelling for prescription drugs as outlined in § 201.100(d) must include the exact information mandated by § 201.57(a), (b), and (c) under the following headings and subheadings, and in the following order:

1. Highlights of Prescribing Information

a) Product Names, Other Required Information

b) Boxed Warning

c) Recent Major Changes

d) Indications and Usage

e) Dosage and Administration

f) Dosage Forms and Strengths

g) Contraindications
h) Warnings and Precautions
i) Adverse Reactions
j) Drug Interactions
k) Use in Specific Populations
2. Full Prescribing Information: Contents
3. Full Prescribing Information

Boxed Warning:
a) Indications and Usage
b) Dosage and Administration
c) Dosage Forms and Strengths
d) Contraindications
e) Warnings and Precautions
f) Adverse Reactions
g) Drug Interactions
h) Use in Specific Populations
• Pregnancy
• Lactation
• Females and Males of Reproductive Potential
• Pediatric use
• Geriatric use
4. Drug Abuse and Dependence
a. Controlled substance
b. Abuse
c. Dependence
d. Over dosage
5. Description
6. Clinical Pharmacology
i. Mechanism of action
ii. Pharmacodynamics
iii. Pharmacokinetics
7. Nonclinical Toxicology
8. Carcinogenesis, mutagenesis, impairment of fertility
9. Animal toxicology and/or pharmacology
10. Clinical Studies
11. References
12. How Supplied/Storage and Handling
13. Patient Counseling Information

Drug labeling requirements in Europe:

CHMP, a body of the European Medicines Agency (EMA), oversees the labeling of human medicines in Europe. According to EU regulations, there are various obligatory requirements. This encompasses the product function, batch number, country, nominal content, DOMD and PAO dates, specific usage warnings and precautions, along with the name and address of the responsible individual. CE is the most commonly acknowledged conformity mark in Europe. Products offered in the European Economic Area are marked with the CE symbol to indicate compliance with health, safety, and environmental protection standards.

In accordance with Articles 54, 55, and 59 of Directive 2001/83/EC from the European Parliament, medical products intended for human use should come with external and/or immediate packaging details (labeling) and a package insert. A package insert is not required when all essential information is shown on the box, as stated in Article 58 of Directive 2001/83/EC. The primary source of regulations for medical labeling requirements in the European Union is Directive 2001/83/EC. Title V of Directive 2001/83/EC includes a comprehensive list of all requirements and elements. This directive establishes the Community code related to human-use pharmaceuticals and includes detailed guidelines for labelling and packaging pharmaceuticals.

To comply with the Labelling requirements for medicinal products, the European Union's (EU) regulatory system for pharmaceutical products heavily relies on the Summary Product Characteristics (SmPCs). Here is an overview of the key roles of SPCs in the context of EU Labelling requirements:

1. Name of medicinal product
2. Qualitative and quantitative composition
3. Pharmaceutical form
4. Clinical Particulars:

a) Therapeutic indications
b) Posology and method of administration
c) Contraindications
d) Special warnings and precautions for use
e) Interaction with other medicinal products and other forms of interaction
f) Fertility, pregnancy and lactation
g) Effects on the ability to drive and use machines
h) Undesirable effects
i) Overdose
j) Pharmacological Properties
k) Pharmacodynamic properties
l) Pharmacokinetic properties
m) Preclinical safety data

5. Pharmaceutical particulars

a) List of excipients
b) Incompatibilities
c) Shelf life
d) Special precautions for storage
e) Nature and contents of container
f) Special Precaution for Cisposal and Other Handling of the product

Effect on Patient Security:

Drug labels provide essential information to consumers and healthcare providers, making them crucial for ensuring patient safety. The completeness, accuracy, and clarity of prescription labels can significantly influence treatment outcomes, medication errors, adverse drug reactions (ADRs), and overall patient safety. Ensuring patient safety is the primary concern in healthcare, with one crucial element being the accurate provision of medications. Drug labeling is an essential resource for providing crucial information to patients and healthcare providers, ensuring the safe use of pharmaceuticals. It includes information on potential side effects, dosage recommendations, contraindications, and proper storage conditions—each of which is essential for preventing errors and ensuring the correct therapeutic outcome. Errors in medication and adverse drug reactions (ADRs) continue to be a significant source of injury in healthcare systems globally, even with the important function of drug labeling.

According to regulatory guidelines from organizations such as the FDA (USA), EMA (Europe), and CDSCO (India), drug labels must be precise, consistent, and clear to minimize medication errors. In regions with stringent regulations, such as the USA and Europe, labels provide essential information including active ingredients, dosage instructions, contraindications, and black box warnings. By helping patients with appropriate medication usage, these minimize the risk of hazardous drug interactions or overdoses.

Additionally, a range of people with diverse literacy abilities, languages, and cultural heritages often use drugs in the era of globalization. As they enhance patient understanding and reduce the likelihood of prescription mistakes, multilingual and culturally aware medicine labels are increasingly essential.

Impact Area	With Strong Regulatory Standards (USA/EU)	With Weaker Enforcement
Patient Safety	High, due to detailed and structured information	Compromised by vague or incomplete labeling
Risk Awareness	Enhanced through boxed warnings and PILs	Limited, especially in low-literacy settings
Medication Adherence	Improved by clear instructions	Lower due to misunderstanding or confusion
Self-Medication Control	Controlled via prescription-only labeling	Common due to poorly enforced label requirements
Comprehension by Public	Tested and optimized for readability	Often technical or poorly translated

Impact of Drug Labels on Patients Safety:

The efficiency of a medication label in encouraging safe use of drugs is directly affected by regulatory standards. Improved patient outcomes are closely associated with robust standards, as seen in the USA and Europe, while adverse drug events and usage are more common in regions of India where regulations are weak or inconsistently applied. Medication labeling significantly impacts patient safety, compliance, and overall health results.

Enhanced patient understanding, reduced medication mistakes, and improved compliance with treatment protocols result from regulatory requirements that necessitate labels that are clear, structured, and easy to read, similar to those set by the FDA and EMA. In contrast, lax enforcement of regulations, seen in some areas of India, results in misinterpretations, misuse, and a heightened chance of negative outcomes. To enhance the effectiveness of healthcare systems globally and ensure patient safety, it is essential to improve and standardize drug labeling processes worldwide.

Future Trends of Drug Labels:

Medication labeling is essential for guaranteeing the safe and effective utilization of drugs. With technological progress and heightened globalization, drug labeling has developed to include contemporary tools and techniques. The incorporation of artificial intelligence is among the emerging technologies in digital labeling, as well as the potential for global standardization to address current challenges and improve the effectiveness, safety, and availability of medications. Developments in digital technologies, artificial intelligence (AI), and global standardization efforts are instigating a significant transformation in drug labeling within the pharmaceutical industry.

Global Integration and Forthcoming Alignment:

The pharmaceutical sector functions within a tightly controlled setting featuring strict labeling regulations and information sharing obligations. Pharmaceutical companies must manage the labeling of various product versions to address the different requirements of patients and healthcare professionals. The globalization of the pharmaceutical industry highlights the need for consistent regional drug labeling practices to improve medication safety, reduce mistakes, and speed up regulatory approvals.

To achieve uniform and effective labeling, it is vital to standardize essential elements like medication names, dosage forms, strengths, and indications by employing a consistent label template that incorporates these important components. Utilizing centralized labeling software can optimize content management, improve version control, and minimize mistakes during creation, review, and approval stages. Collaboration across Regulatory Affairs, Marketing, Quality Control, and Packaging teams is essential to align labelling strategies and ensure accurate product information. Streamlining and unifying information through clear visuals, consistent icons, and succinct wording enhances readability and alleviates information fatigue for patients and healthcare providers, ensuring safety and important guidance are emphasized. Ultimately, performing user testing and collecting input from patients, healthcare professionals, and user experience specialists allows for ongoing enhancement through iterative design, guaranteeing that the labels are effective and easy to use.

Result and Discussion:

A comparative analysis of prescription drug labelling in the United States, Europe, and India reveals significant differences in regulatory frameworks, enforcement, language requirements, and patient information standards. The U.S. and EU maintain robust, standardized, and patient-centric labelling systems enforced by the FDA and EMA, respectively, ensuring clear, consistent, and accessible drug information.

They require extensive patient brochures, organized content layouts, tracking systems, and specific cautions. In comparison, India, overseen by the CDSCO, displays more variability in label formats, inconsistent enforcement, and minimal obligations for patient information, particularly for drugs that aren't high-risk. India's system has key components, but it requires modernization and alignment with global best practices to enhance safety, understanding, and public health results.



Conclusion:

This comparative study highlights the crucial role of regulatory frameworks in shaping prescription drug labeling across the United States, Europe, and India. Every area employs a distinct approach, influenced by its legal systems, healthcare facilities, linguistic variations, and public health requirements. Despite these differences, all three regions aim to ensure that drug labeling aids in the safe, effective, and informed usage of medications by doctors and patients.

The similarities and distinctions in prescription medication labeling regulations among the United States, the European Union, and India emphasize unique regulatory focuses influenced by each area's legal structures, health care systems, and governance abilities. In the United States, the Food and Drug Administration (FDA) has developed a highly organized, digitally accessible labeling system that emphasizes clarity, thoroughness, and uniformity in the Structured Product Labelling (SPL) format. The system enables electronic integration and support for clinical decision-making via updated and standardized information.

In contrast, the European Union—led by the European Medicines Agency (EMA)—employs a more decentralized yet coordinated approach. The EU highlights the importance of multilingual labeling requirements, patient information leaflets, and accessibility across borders, taking into account the linguistic and cultural diversity among member states. Aspects of risk reduction and pharmacovigilance are firmly integrated into EU labeling regulations.

India, regulated by the Central Drugs Standard Control Organization (CDSCO), is revising its drug labeling guidelines to align more closely with international standards. While traditionally less extensive, Indian regulations are undergoing reforms to improve transparency, strengthen regulatory oversight, and incorporate essential elements like patient education, digital integration, and pharmacovigilance.

The comparative analysis reveals several significant differences: the level of detail required, the method of information presentation (digital versus tangible), language considerations, and the extent of patient engagement. These differences can pose difficulties for global pharmaceutical firms in maintaining compliance across regions, yet they also create chances for regulatory alignment and sharing of best practices.

Ultimately, this study advocates for a cooperative global dialogue among regulatory bodies to identify optimal practices and establish universal yet adaptable labeling frameworks. This would enhance global drug information, reduce health disparities, and ensure that patients everywhere access safe and effective treatments supported by clear, consistent, and comprehensible labeling.

References:

1. USFDA, 21 CFR (Code of Federal Regulation), PART 201, Subpart C; 4/12/2025 https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-201/subpart-C.
2. Annamalai University. (n.d.). B.Pharm. 4-year 8th semester 805AT: Pharmaceutical packaging.AnnamalaiUniversity.RetrievedJune12,2022, from https://annamalaiuniversity.ac.in/studport/download/engg/pharm/resources/BPHARM_4Y_8S_805AT_Pharm.Packaging.pdf
3. Wikipedia contributors. (n.d.). Drug labelling. Wikipedia. From: https://en.wikipedia.org/wiki/Drug_labelling
4. Best Practice Guidance on the Labeling and Packaging of Medicines. 2015. Nov,Availablefrom:https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/474366/Best_practice_guidance_Labeling_and_packaging_of_medicines.pdf.
5. Scilife. (n.d.). Pharmaceutical labeling requirements. Scilife. Retrieved April 29, 2024, from https://www.scilife.io/glossary/pharmaceutical-labeling.
6. Shrank, W. H., Agnew-Blais, J., Choudhry, N. K., Wolf, M. S., Orav, E. J., Avorn, J., & Fischer, M. A. (2007). A patient-centered prescription drug label to promote appropriate medication use and adherence. Archives of Internal Medicine, 167(16), 1648–1655. https://doi.org/10.1001/archinte.167.16.1648
7. Shrank,W.H.,Avorn,J.,Rolon,C.,&Shekelle,P.(2007).Effectofcontentand format of prescription drug labels on readability, understanding, and medication use: A systematic review. Annals of Pharmacotherapy, 41(5), 783–801.
8. Wolf, M. S., Davis, T. C., Shrank, W., Neuberger, M., &Parker, R.M.(2007). To err is human: Patient misinterpretations of prescription drug label instructions. Patient Education and Counselling, 67(3), 293–300. https://doi.org/10.1016/j.pec.2007.03.024.

9. Pharmahelp.(2020,March28).Importanceoflabelinginthepharmaceutical industry, from https://pharmahelp.in/importance-of-labeling-in-the-pharmaceutical-industry.
10. U.S. Food and Drug Administration. (n.d.). Generic drugs - specific labeling resources. U.S. Department of Health and Human Services. from https://www.fda.gov/drugs/fdas-labeling-resources-human-prescription-drugs/generic-drugs-specific-labeling-resources.
11. Shionogi Pharma. (2010). Ulesfia lotion: Highlights of prescribing information. http://www.ulesfialotion.com/pdf/Ulesfia_Prescribing_Information.pdf.
12. Basic Understanding drug labels. Basic Medical Key. https://basicmedicalkey.com/understanding-drug-labels/
13. Central Drugs Standard Control Organization. (n.d.). Labelling & packaging of drugs as per Drugs and Cosmetic Act. Ministry of Health and Family Welfare, Government of India. 21st December, 1945, from https://drugscontrol.org/pdf/labelling.pdf
14. U.S.Food and Drug Administration.(2011,October).Warnings and precautions, contraindications, and box edwarning sections of labeling for human prescription drug and biological products—Content and format (Guidance for Industry).U.S.Department of Health and Human Services. https://www.fda.gov/files/drugs/published/Warnings-and-Precautions--Contraindications--and-Boxed-Warning-Sections-of-Labeling-for-Human-Prescription-Drug-and-Biological-Products-%E2%80%94-Content-and-Format.pdf
15. U.S.Foodand Drug Administration.(n.d.).National Drug Code database background information. U.S. Department of Health and Human Services. https://www.fda.gov/drugs/development-approval-process-drugs/national-drug-code-database-background-information
16. U.S.Food and Drug Administration.(2018).Prescription drug labeling.

    Retrievedfromhttps://www.fda.gov/drugs/information-consumers-and-patients-drugs/prescription-drug-labeling-resources
17. Government of India. Ministry of Health and Family Welfare. The Drugs and Cosmetic Act 1940 and the Rules 1945. India: Government of India. Ministry of Health and Family Welfare; 2016. Dec 31.
18. Makvana, S. H., Deshpande, S., & Zaveri, M. (2024). Comparative analysis of drug labeling requirements in the USA and India: Regulatory frameworks and compliance standards. International Journal of Pharmaceutical Sciences, 2(6), 701–707.
19. Vikas, Mittal,R.,Kumar,M.,Rashi,Mittal,N.,&Shweta.(2021).Guidelines for drug package inserts in India and United States: A comparative review.
20. Vasa Lakshmi Sravanthi, Raju Kamaraj. Regulatory Labeling Requirements and its Labeling Comparison between US and EU. Research J.Pharm. and Tech 2018; 11(11): 4875-4877.
21. Coleman, J. J., & Pontefract, S. K. (2016). Adverse drug reactions. Clinical Medicine, 16(5), 481–485. https://doi.org/10.7861/clinmedicine.16-5-481